{"id":349146,"date":"2026-11-17T09:32:50","date_gmt":"2026-11-17T04:02:50","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=349146"},"modified":"2026-11-17T09:32:50","modified_gmt":"2026-11-17T04:02:50","slug":"epigral-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/","title":{"rendered":"Epigral Share Price Target 2027: Can It Reach Rs 1,353? Base Case at Rs 1,129"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Epigral share price Rs 949.05 (17 November 2026). Base target Rs 1,129, bull Rs 1,353, downside risk Rs 753. PE 14.25. 52W range Rs 807.00 to Rs 1,535.20.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Epigral share price target<\/strong> for 2027 is <strong>Rs 1,129<\/strong>, about <strong>19.0%<\/strong> above the current price of Rs 949.05. The <strong>bull case<\/strong> is <strong>Rs 1,353<\/strong>, and the <strong>downside risk level<\/strong>, which is not a target, is <strong>Rs 753<\/strong>. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 27.8%, with the stock holding its PE of 14.25. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a <strong>Epigral target price<\/strong> for 2027 should start with where the stock sits today. At Rs 949.05 on 17 November 2026, it is 38.2% below its 52-week high of Rs 1,535.20 and 17.6% above its 52-week low of Rs 807.00. That range spans 90% from low to high, so the entry point matters as much as the <strong>Epigral price forecast<\/strong> itself.<\/p>\n<p>This article builds the <strong>Epigral share price target<\/strong> from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the <strong>bull case<\/strong> and the <strong>downside risk level<\/strong> were reached and test them against your own view.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=epigral-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Epigral_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Epigral Stock Analysis: Company Overview and Key Stats\">Epigral Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Why_Is_Epigral_Share_Price_Target_Set_at_Rs_1129_for_2027\" title=\"Why Is Epigral Share Price Target Set at Rs 1,129 for 2027?\">Why Is Epigral Share Price Target Set at Rs 1,129 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Earnings_Growth_Behind_the_Epigral_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Epigral Target Price: Five Years of Results\">Earnings Growth Behind the Epigral Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Valuation_Check_for_the_Epigral_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Epigral Stock Target: PE, Price to Book and ROE\">Valuation Check for the Epigral Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Epigral_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Epigral Share Price Targets for the Short Term and 12 Months\">Epigral Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Short_Term_Epigral_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Epigral Stock Target Levels: Technical Setup\">Short Term Epigral Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#12_Month_Epigral_Target_Price_for_2027\" title=\"12 Month Epigral Target Price for 2027\">12 Month Epigral Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Epigral_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Epigral Target Price\">How EPS Growth and PE Multiple Change the Epigral Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Epigral_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Epigral Stock Target in 2027\">Bull Case and Downside Risk for Epigral Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Bull_Case_Rs_1353\" title=\"Bull Case Rs 1,353\">Bull Case Rs 1,353<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Downside_Risk_Level_Rs_753\" title=\"Downside Risk Level Rs 753\">Downside Risk Level Rs 753<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Key_Risks_to_the_Epigral_Target_Price_for_2027\" title=\"Key Risks to the Epigral Target Price for 2027\">Key Risks to the Epigral Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Epigral_Price_Target\" title=\"Growth Slowdown Risk for the Epigral Price Target\">Growth Slowdown Risk for the Epigral Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#How_to_Invest_in_Epigral\" title=\"How to Invest in Epigral\">How to Invest in Epigral<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#FAQs_on_Epigral_Share_Price_Target_2027\" title=\"FAQs on Epigral Share Price Target 2027\">FAQs on Epigral Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#What_is_the_Epigral_share_price_target_for_2027\" title=\"What is the Epigral share price target for 2027?\">What is the Epigral share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#What_is_the_Epigral_share_price_today\" title=\"What is the Epigral share price today?\">What is the Epigral share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Is_Epigral_a_buy_or_sell_at_the_current_price\" title=\"Is Epigral a buy or sell at the current price?\">Is Epigral a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Epigral_shares\" title=\"What are the bull case target and downside risk level for Epigral shares?\">What are the bull case target and downside risk level for Epigral shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#What_are_the_main_risks_to_the_Epigral_price_target\" title=\"What are the main risks to the Epigral price target?\">What are the main risks to the Epigral price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#What_is_the_PE_ratio_of_Epigral_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Epigral and how does it compare with the industry?\">What is the PE ratio of Epigral and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#Who_owns_Epigral_and_what_is_the_promoter_holding\" title=\"Who owns Epigral, and what is the promoter holding?\">Who owns Epigral, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/epigral-share-price-target-2027\/#What_were_Epigrals_latest_quarterly_results\" title=\"What were Epigral&#8217;s latest quarterly results?\">What were Epigral&#8217;s latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Epigral_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Epigral Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Epigral (NSE: EPIGRAL) has a market capitalisation of Rs 4,060 crore. In FY26 it reported revenue of Rs 2,542 crore and net profit of Rs 331.97 crore. The table collects the figures the <strong>Epigral share price target<\/strong> is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/epigral\/epigral-ltd-share-price-today\">Epigral<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>EPIGRAL<\/td>\n<\/tr>\n<tr>\n<td>CMP (17 November 2026)<\/td>\n<td>Rs 949.05<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 1,535.20<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 807.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 4,060 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>14.25<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>33.54<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>1.72<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>12.05%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.24<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 66.03<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.53%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 1,129<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 1,353<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 753<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Epigral_Share_Price_Target_Set_at_Rs_1129_for_2027\"><\/span><strong>Why Is Epigral Share Price Target Set at Rs 1,129 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The arithmetic is short. Trailing EPS of Rs 66.03 grown for one year gives a forward <strong>EPS estimate<\/strong> of Rs 79.24, and multiplying it by the unchanged PE of 14.25 gives the <strong>Rs 1,129<\/strong> base-case <strong>Epigral stock target<\/strong>. The <strong>bull case<\/strong> adds faster earnings growth and a higher multiple, while the <strong>downside risk level<\/strong> assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Epigral_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Epigral Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Epigral grew revenue from Rs 1,555 crore in FY22 to Rs 2,542 crore in FY26, a compound annual growth rate of 13.1%. Net profit grew more slowly, from Rs 252.79 crore to Rs 331.97 crore (7.0% a year), which points to margin pressure alongside the sales growth.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>1,555.05<\/td>\n<td>252.79<\/td>\n<td>60.84<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>2,196.38<\/td>\n<td>353.29<\/td>\n<td>85.03<\/td>\n<td>5.00<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>1,935.76<\/td>\n<td>195.87<\/td>\n<td>47.14<\/td>\n<td>5.00<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>2,565.34<\/td>\n<td>357.69<\/td>\n<td>84.68<\/td>\n<td>6.00<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>2,542.16<\/td>\n<td>331.97<\/td>\n<td>76.95<\/td>\n<td>5.00<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was -0.9%, slower than the four-year average of 13.1%, and net profit moved down 7.2%. EPS rose from Rs 47.14 in FY24 to Rs 76.95 in FY26. The <strong>FY27 outlook<\/strong> for the <strong>Epigral price target<\/strong> depends on whether that <strong>EPS estimate<\/strong> keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Epigral converted 13.1% of FY26 revenue into net profit, against 13.9% in FY25, within a five-year range of 10.1% to 16.3%. EBITDA margin was 22.9% in FY26 versus 28.3% in FY25.<\/p>\n<p>In the September 2026 quarter, revenue was Rs 751.81 crore, up 27.6% from the same quarter a year earlier, while net profit of Rs 65.08 crore was up 27.1%. EBITDA came in at Rs 141.93 crore, up 5.8% year on year. The next quarterly result is the first test of whether the earnings assumption behind the <strong>Epigral stock target<\/strong> holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.24, and shareholders&#8217; equity grew from Rs 725.97 crore in FY22 to Rs 2,221 crore in FY26. Operating cash flow in FY26 was Rs 435.53 crore against capital expenditure of Rs 394.15 crore, leaving free cash flow of Rs 41.38 crore, or 1.0% of the current market capitalisation. In FY25 free cash flow was Rs 245.87 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Epigral_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Epigral Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 14.25 against an industry PE of 33.54, Epigral trades at a discount to its industry. Price to book is 1.72 on a book value of Rs 548.13 per share, and return on equity is 12.05%. A PE of 14.25 equals an earnings yield of 7.0%, and the FY26 dividend of Rs 5.00 per share gives a yield of 0.53%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 68.83% of Epigral in September 2026, and promoter holding has stayed near 68.83% since September 2025. Foreign institutional investors (FII) held 0.99% and domestic institutions (DII) held 4.90%, which puts total <strong>institutional holding<\/strong> at 5.89%. FII holding fell from 2.71% in September 2025 to 0.99% in September 2026. Public shareholders own the remaining 25.29%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Epigral_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Epigral Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Epigral_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Epigral Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 949.05 on 17 November 2026, Epigral trades below its 50-day simple moving average of Rs 1,011.97 and below its 200-day exponential moving average of Rs 1,131.95. The 14-day RSI reads 58.2, which is neutral territory, and the MACD line sits above its signal line. The nearest <strong>resistance level<\/strong> is Rs 1,011.97 (50-day simple moving average) and the nearest support is Rs 807.00 (52-week low). A sustained move above Rs 1,011.97 would improve the short-term setup, while a close below Rs 807.00 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Epigral_Target_Price_for_2027\"><\/span><strong>12 Month Epigral Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>12-month target<\/strong> of <strong>Rs 1,129<\/strong> means a move of 19.0% up from Rs 949.05 over the next 12 months. It would still leave the stock 26.5% below its 52-week high of Rs 1,535.20. Anyone checking the <strong>Epigral share price target<\/strong> against their own view should focus on two inputs: the EPS estimate and the <strong>PE multiple<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Epigral_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Epigral Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 11.40<\/th>\n<th>PE 14.25<\/th>\n<th>PE 16.39<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 66.03)<\/td>\n<td>Rs 753<\/td>\n<td>Rs 941<\/td>\n<td>Rs 1,082<\/td>\n<\/tr>\n<tr>\n<td>20.0% (EPS Rs 79.24)<\/td>\n<td>Rs 903<\/td>\n<td>Rs 1,129<\/td>\n<td>Rs 1,299<\/td>\n<\/tr>\n<tr>\n<td>25.0% (EPS Rs 82.54)<\/td>\n<td>Rs 941<\/td>\n<td>Rs 1,176<\/td>\n<td>Rs 1,353<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the <strong>Epigral price forecast<\/strong>, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Epigral_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Epigral Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_1353\"><\/span><strong>Bull Case Rs 1,353<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case<\/strong> <strong>Epigral price target<\/strong> needs EPS growth of 25.0%, which lifts forward EPS to Rs 82.54, and a <strong>PE multiple<\/strong> that rises 15% to 16.39. That gives <strong>Rs 1,353<\/strong>, 42.6% above the current price and below the 52-week high of Rs 1,535.20.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_753\"><\/span><strong>Downside Risk Level Rs 753<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 66.03 and the PE falls 20% to 11.40. That gives <strong>Rs 753<\/strong>, 20.7% below the current price and below the 52-week low of Rs 807.00.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>25.0%<\/td>\n<td>16.39<\/td>\n<td>Rs 1,353<\/td>\n<td>+42.6%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>20.0%<\/td>\n<td>14.25<\/td>\n<td>Rs 1,129<\/td>\n<td>+19.0%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>11.40<\/td>\n<td>Rs 753<\/td>\n<td>-20.7%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Epigral_Target_Price_for_2027\"><\/span><strong>Key Risks to the Epigral Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Epigral_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Epigral Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the September 2026 quarter was up 27.6% year on year, and FY26 revenue growth was -0.9%. If growth slows from here, the EPS estimate behind the Epigral stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Epigral has a market capitalisation of Rs 4,060 crore. <strong>Institutional holding<\/strong> is 5.89%, and promoters hold 68.83%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 13.1% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 14.25 versus an industry PE of 33.54, a de-rating toward the downside-risk PE of 11.40 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Technical indicators add short-term risk: the 14-day RSI is 58.2 and the MACD sits above its signal line. A broad fall in the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> or the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> can override company fundamentals for weeks at a time. That applies to any Epigral stock target, however carefully it is built.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Epigral\"><\/span><strong>How to Invest in Epigral<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any <strong>Epigral share price target<\/strong> is only as current as the data behind it, and the data here is as of 17 November 2026, so refresh the Rs 949.05 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Epigral&#8217;s PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Epigral fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three <strong>Epigral target price<\/strong> scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and <strong>resistance level<\/strong>s above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Epigral live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Epigral share price target<\/strong> for 2027 is Rs 1,129 in the base case, with <strong>Rs 1,353<\/strong> as the bull case. The support for that view is arithmetic you can check: EPS grew 27.8% a year over FY24 to FY26, and the stock trades at a PE of 14.25. The risks are equally concrete, including a valuation that can de-rate if growth disappoints and a downside scenario that cuts the price 21% if earnings stall. Use these numbers as a framework for judging the <strong>Epigral price target<\/strong>, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Epigral_Share_Price_Target_2027\"><\/span><strong>FAQs on Epigral Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Epigral_share_price_target_for_2027\"><\/span><strong>What is the Epigral share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Epigral share price target for 2027 is Rs 1,129, which is 19.0% above the price of Rs 949.05 on 17 November 2026. The bull case is Rs 1,353 and the downside risk level, which is not a target, is Rs 753. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Epigral_share_price_today\"><\/span><strong>What is the Epigral share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 17 November 2026, before market open, Epigral (NSE: EPIGRAL) is quoted at Rs 949.05, which is its last closing price from the previous session. That is 38.2% below the 52-week high of Rs 1,535.20 and 17.6% above the 52-week low of Rs 807.00. The market capitalisation of Rs 4,060 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Epigral_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Epigral a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data points both ways. On the positive side, EPS has grown 27.8% a year over FY24 to FY26 and the base case implies 19.0% upside; on the cautious side, the stock sits 38.2% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 753 is 21% below the current price. Whether Epigral fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Epigral_shares\"><\/span><strong>What are the bull case target and downside risk level for Epigral shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case in the Epigral share price target for 2027 is Rs 1,353, which assumes 25.0% EPS growth and a PE of 16.39, a 15% re-rating from today&#8217;s multiple. That is 42.6% above the current price and below the 52-week high of Rs 1,535.20. The downside risk level is Rs 753, which assumes flat EPS and a PE of 11.40, 20% lower than today. It sits 20.7% below the current price and below the 52-week low of Rs 807.00, and it marks a risk to watch, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Epigral_price_target\"><\/span><strong>What are the main risks to the Epigral price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Four risks matter most for the Epigral share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 4,060 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 11.40 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Epigral_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Epigral and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Epigral is 14.25, against an industry PE of 33.54, which is a discount to the industry. Price to book is 1.72 and return on equity is 12.05%, and the PE equals an earnings yield of 7.0%. The base case holds the PE unchanged, so the Epigral share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Epigral_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Epigral, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 68.83% of Epigral in September 2026. FII held 0.99%, DII held 4.90% and the public held 25.29%. Together the two institutional groups hold 5.89%. Shareholding is filed every quarter, so it is worth rechecking after each result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Epigrals_latest_quarterly_results\"><\/span><strong>What were Epigral&#8217;s latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the September 2026 quarter, Epigral reported revenue of Rs 751.81 crore (up 27.6% year on year) and net profit of Rs 65.08 crore (up 27.1%). For comparison, FY26 full-year revenue growth was -0.9% and net profit moved down 7.2%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Epigral share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Epigral share price target for 2027 is Rs 1,129, which is 19.0% above the price of Rs 949.05 on 17 November 2026. The bull case is Rs 1,353 and the downside risk level, which is not a target, is Rs 753. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.\"}},{\"@type\":\"Question\",\"name\":\"What is the Epigral share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 17 November 2026, before market open, Epigral (NSE: EPIGRAL) is quoted at Rs 949.05, which is its last closing price from the previous session. That is 38.2% below the 52-week high of Rs 1,535.20 and 17.6% above the 52-week low of Rs 807.00. The market capitalisation of Rs 4,060 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.\"}},{\"@type\":\"Question\",\"name\":\"Is Epigral a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data points both ways. On the positive side, EPS has grown 27.8% a year over FY24 to FY26 and the base case implies 19.0% upside; on the cautious side, the stock sits 38.2% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 753 is 21% below the current price. Whether Epigral fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Epigral shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case in the Epigral share price target for 2027 is Rs 1,353, which assumes 25.0% EPS growth and a PE of 16.39, a 15% re-rating from today's multiple. That is 42.6% above the current price and below the 52-week high of Rs 1,535.20. The downside risk level is Rs 753, which assumes flat EPS and a PE of 11.40, 20% lower than today. It sits 20.7% below the current price and below the 52-week low of Rs 807.00, and it marks a risk to watch, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Epigral price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four risks matter most for the Epigral share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 4,060 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 11.40 would cut the price even if earnings hold.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Epigral and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Epigral is 14.25, against an industry PE of 33.54, which is a discount to the industry. Price to book is 1.72 and return on equity is 12.05%, and the PE equals an earnings yield of 7.0%. The base case holds the PE unchanged, so the Epigral share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Epigral, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 68.83% of Epigral in September 2026. FII held 0.99%, DII held 4.90% and the public held 25.29%. Together the two institutional groups hold 5.89%. Shareholding is filed every quarter, so it is worth rechecking after each result.\"}},{\"@type\":\"Question\",\"name\":\"What were Epigral's latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the September 2026 quarter, Epigral reported revenue of Rs 751.81 crore (up 27.6% year on year) and net profit of Rs 65.08 crore (up 27.1%). For comparison, FY26 full-year revenue growth was -0.9% and net profit moved down 7.2%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Epigral share price target 2027: base Rs 1,129, bull Rs 1,353, downside risk level Rs 753, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":34,"featured_media":349145,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-349146","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["349145"],"rank_math_title":["Epigral Share Price Target 2027: 19.0% Upside, Bull Rs 1,353"],"rank_math_description":["The Epigral share price target for 2027 is Rs 1,129 against a price of Rs 949.05. Bull case, downside risk, earnings trend and risks explained. November 2026."],"rank_math_focus_keyword":["Epigral share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/epigral-share-price-target-2027-can-it-reach-rs-1-353-base-case-at-rs-1-129.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=349146"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349146\/revisions"}],"predecessor-version":[{"id":349147,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349146\/revisions\/349147"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/349145"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=349146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=349146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=349146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}